During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the ...

An analysis of pivotal phase 3 trials shows supplements to arrest age-related macular degeneration have no effect on ...

Ollin Biosciences has officially launched with $100 million in funding to advance a pipeline of therapies for ...

A new study published in the Journal of American Medical Association found that patients with exudative age-related macular ...

The use of anticoagulants or antiplatelets was linked to a higher risk of intraocular hemorrhage requiring vitrectomy in ...

Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) ...

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial ...

IRON MOUNTAIN — Garrett Eye Center in Iron Mountain is offering a new non-invasive treatment for early stage dry macular ...

BrightFocus Foundation today launched two new national public service announcements, Stop AMD and Stop Glaucoma, to raise awareness of macular degeneration and glaucoma, leading causes of irreversible ...